New Ray Medicine International Holding Limited, incorporated in Bermuda with limited liability, announced its Monthly Return for Equity Issuer for the period ended 31 October 2025. The total authorized share capital remained at 15,000,000,000 ordinary shares, each with a par value of HKD 0.01, amounting to HKD 150,000,000 in total.

The number of issued ordinary shares stayed at 167,184,665, with no treasury shares recorded. There were 12,820,000 outstanding share options under the company’s share option scheme, and no new shares were issued or treasury shares transferred pursuant to these options during the reporting month. No other warrants, convertibles, or related arrangements were disclosed for the period.